Galectin Therapeutics (GALT) Financials

Galectin Therapeutics logo
$3.02 -0.03 (-0.98%)
As of 11/16/2026 04:00 PM Eastern
Annual Income Statements for Galectin Therapeutics

Annual Income Statements for Galectin Therapeutics

This table shows Galectin Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-21 -22 -17 -15 -20 -24 -31 -39 -45 -47 -31
Consolidated Net Income / (Loss)
-20 -21 -16 -14 -13 -23 -31 -39 -41 -47 -31
Net Income / (Loss) Continuing Operations
-20 -21 -16 -14 -13 -23 -31 -39 -41 -47 -31
Total Pre-Tax Income
-20 -21 -16 -14 -13 -23 -31 -39 -41 -47 -31
Total Operating Income
-20 -21 -16 -14 -13 -23 -30 -38 -38 -42 -20
Total Gross Profit
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses
20 21 16 14 13 23 30 38 38 42 20
Selling, General & Admin Expense
6.97 6.16 4.53 7.13 5.97 5.47 6.36 6.62 5.94 5.86 5.80
Research & Development Expense
13 15 12 6.47 7.47 18 24 32 32 37 14
Total Other Income / (Expense), net
0.05 0.05 0.01 -0.30 0.14 -0.02 -0.35 -0.42 -2.99 -4.61 -11
Interest Expense
- - 0.01 0.34 0.09 0.09 0.49 1.03 2.79 5.54 7.33
Interest & Investment Income
0.05 0.05 0.02 0.04 0.23 0.07 0.00 0.05 0.23 0.34 0.13
Other Income / (Expense), net
- - - - - 0.00 0.14 0.56 -0.43 0.59 -3.55
Preferred Stock Dividends Declared
1.10 0.91 1.23 1.15 0.26 0.14 0.17 0.10 0.12 0.15 0.14
Basic Earnings per Share
($0.88) ($0.76) ($0.49) ($0.38) ($0.39) ($0.41) ($0.52) ($0.65) ($0.74) ($0.76) ($0.48)
Weighted Average Basic Shares Outstanding
24.12M 29.22M 35.52M 39.41M 52.24M 57.03M 58.53M 59.39M 60.16M 62.31M 63.90M
Diluted Earnings per Share
($0.88) ($0.76) ($0.49) ($0.38) ($0.39) ($0.41) ($0.52) ($0.65) ($0.74) ($0.76) ($0.48)
Weighted Average Diluted Shares Outstanding
24.12M 29.22M 35.52M 39.41M 52.24M 57.03M 58.53M 59.39M 60.16M 62.31M 63.90M
Weighted Average Basic & Diluted Shares Outstanding
24.12M 29.22M 35.52M 39.41M 52.24M 57.03M 59.36M 59.44M 61.90M 63.18M 65.83M

Quarterly Income Statements for Galectin Therapeutics

This table shows Galectin Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Total Costs & Expenses
- - - - - 4.63 4.20 - - 3.98 3.37
Net Income / (Loss) Attributable to Common Shareholders
-11 -12 -11 -12 -9.61 -7.58 -8.22 -5.56 -5.07 -9.18 -3.57
Consolidated Net Income / (Loss)
-11 -12 -11 -12 -9.63 -7.52 -8.18 -5.50 -5.05 -9.11 -3.53
Net Income / (Loss) Continuing Operations
-11 -12 -11 -12 -9.63 -7.52 -8.18 -5.50 -5.05 -9.11 -3.53
Total Pre-Tax Income
-11 -12 -11 -12 -9.63 -7.52 -8.18 -5.50 -5.05 -9.11 -3.53
Total Operating Income
-9.65 -11 -9.07 -12 -7.90 -4.63 -4.20 -3.37 -4.08 -3.98 -3.37
Total Gross Profit
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Operating Expenses
9.65 11 9.07 12 7.90 4.63 4.20 3.37 4.08 3.98 3.37
Selling, General & Admin Expense
1.59 1.48 1.47 1.32 1.41 1.36 1.59 1.43 1.85 1.85 1.80
Research & Development Expense
8.05 9.81 7.60 11 6.49 3.26 2.61 1.93 2.23 2.14 1.56
Total Other Income / (Expense), net
-1.84 -1.08 -2.15 0.46 -1.73 -2.90 -3.99 -2.14 -0.97 -5.13 -0.16
Interest Expense
1.05 1.27 1.49 1.73 1.74 1.83 1.82 1.94 1.99 2.00 0.79
Interest & Investment Income
0.08 0.08 0.09 0.09 0.04 0.03 0.04 0.03 0.04 0.03 0.03
Other Income / (Expense), net
-0.87 0.11 -0.75 2.10 -0.03 -1.10 -2.21 -0.22 0.98 -3.16 0.59
Preferred Stock Dividends Declared
0.01 0.06 0.02 0.06 -0.03 0.06 0.04 0.06 0.02 0.06 0.04
Basic Earnings per Share
($0.19) ($0.20) ($0.18) ($0.19) ($0.15) ($0.12) ($0.13) ($0.08) ($0.08) ($0.14) ($0.04)
Weighted Average Basic Shares Outstanding
61.98M 62.23M 62.28M 62.31M 63.20M 63.45M 64.21M 63.90M 65.78M 65.88M 89.62M
Diluted Earnings per Share
($0.19) ($0.20) ($0.18) ($0.19) ($0.15) ($0.12) ($0.13) ($0.08) ($0.08) ($0.14) ($0.04)
Weighted Average Diluted Shares Outstanding
61.98M 62.23M 62.28M 62.31M 63.20M 63.45M 64.21M 63.90M 65.78M 65.88M 89.62M
Weighted Average Basic & Diluted Shares Outstanding
62.15M 62.28M 62.76M 63.18M - 64.06M 64.47M 0.00 65.86M 100.85M 100.88M

Annual Cash Flow Statements for Galectin Therapeutics

This table details how cash moves in and out of Galectin Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
-3.28 -10 -12 5.20 39 -20 13 -21 7.07 -11 2.60
Net Cash From Operating Activities
-17 -16 -16 -10 -11 -21 -24 -31 -33 -42 -24
Net Cash From Continuing Operating Activities
-17 -16 -16 -10 -11 -21 -24 -31 -33 -42 -24
Net Income / (Loss) Continuing Operations
-20 -21 -16 -14 -13 -23 -31 -39 -41 -47 -31
Consolidated Net Income / (Loss)
-20 -21 -16 -14 -13 -23 -31 -39 -41 -47 -31
Amortization Expense
- - - - 0.04 0.04 0.04 0.03 0.03 0.04 0.05
Non-Cash Adjustments To Reconcile Net Income
3.40 2.48 1.15 4.79 1.77 1.89 2.22 2.72 3.39 2.96 6.30
Changes in Operating Assets and Liabilities, net
-0.32 2.54 -0.82 -1.11 0.64 0.94 3.96 4.97 4.68 2.28 0.61
Net Cash From Investing Activities
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Cash From Continuing Investing Activities
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Cash From Financing Activities
14 5.93 3.58 15 50 0.26 37 10 40 31 26
Net Cash From Continuing Financing Activities
14 5.93 3.58 15 50 0.26 37 10 40 31 26
Issuance of Debt
- - - - - 0.00 30 10 30 30 21
Issuance of Common Equity
14 5.93 3.58 15 50 0.26 6.81 - - 0.00 3.24
Other Financing Activities, net
- - - - - - - 0.00 10 1.23 2.24

Quarterly Cash Flow Statements for Galectin Therapeutics

This table details how cash moves in and out of Galectin Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
-2.11 2.04 1.46 -12 -7.69 6.34 -2.25 6.20 -3.61 -0.84 -1.56
Net Cash From Operating Activities
-12 -8.33 -8.54 -13 -7.69 -6.60 -3.54 -6.04 -3.87 -2.44 -2.27
Net Cash From Continuing Operating Activities
-12 -8.25 -8.54 -13 -7.69 -6.60 -3.54 -6.04 -3.87 -2.44 -2.27
Net Income / (Loss) Continuing Operations
-11 -12 -11 -12 -9.63 -7.52 -8.18 -5.50 -5.05 -9.11 -3.53
Consolidated Net Income / (Loss)
-11 -12 -11 -12 -9.63 -7.52 -8.18 -5.50 -5.05 -9.11 -3.53
Amortization Expense
0.01 - 0.01 0.01 0.01 0.00 - 0.04 0.01 0.00 0.03
Non-Cash Adjustments To Reconcile Net Income
1.68 0.95 1.56 -1.16 0.84 1.95 2.92 0.60 -0.14 4.28 0.41
Changes in Operating Assets and Liabilities, net
-2.31 3.15 1.11 0.33 1.09 -1.03 1.73 -1.18 1.31 2.39 0.83
Net Cash From Financing Activities
10 10 10 0.85 0.00 13 1.30 12 0.26 1.60 0.70
Net Cash From Continuing Financing Activities
10 10 10 0.85 0.00 13 1.30 12 0.26 1.60 0.70
Issuance of Common Equity
- - - - - - 0.85 1.16 - - 0.60
Other Financing Activities, net
- 0.38 - 0.85 - - 0.44 1.07 - - 0.10

Annual Balance Sheets for Galectin Therapeutics

This table presents Galectin Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
26 16 4.16 9.01 48 30 42 21 28 17 20
Total Current Assets
26 16 3.82 8.83 48 29 42 21 28 17 19
Cash & Equivalents
26 15 3.05 8.25 47 27 40 19 26 15 18
Prepaid Expenses
0.55 0.43 0.77 0.58 0.73 2.32 2.17 1.96 2.05 2.13 1.72
Plant, Property, & Equipment, net
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets
0.01 0.00 0.34 0.17 0.26 0.14 0.01 0.73 0.49 0.24 0.10
Other Noncurrent Operating Assets
- - 0.34 0.17 0.26 0.14 - 0.73 0.49 0.24 0.10
Total Liabilities & Shareholders' Equity
26 16 4.16 9.01 48 30 42 21 28 17 20
Total Liabilities
1.36 3.78 2.97 2.11 2.87 5.41 39 53 88 121 146
Total Current Liabilities
1.36 3.78 2.97 2.11 2.82 5.40 9.03 13 16 35 8.03
Short-Term Debt
- - - - - - - - 0.00 21 0.00
Accounts Payable
0.45 0.91 0.61 0.30 1.66 1.29 1.81 3.89 6.43 5.66 3.25
Accrued Expenses
0.85 2.80 2.29 1.51 1.09 4.04 7.16 9.06 9.18 8.20 4.72
Dividends Payable
0.07 0.07 0.07 0.30 0.07 0.07 0.07 0.06 0.06 0.06 0.06
Other Current Liabilities
- - - - - - - - 0.00 0.37 0.00
Total Noncurrent Liabilities
0.00 0.00 0.00 0.00 0.05 0.01 30 40 73 85 138
Long-Term Debt
- - - - - 0.00 29 9.86 72 85 134
Other Noncurrent Operating Liabilities
- - - - 0.05 0.01 1.13 31 1.02 0.05 3.96
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest
7.01 1.72 1.72 1.72 1.72 1.72 1.72 1.72 1.72 1.72 1.72
Total Equity & Noncontrolling Interests
18 10 -0.53 5.18 44 22 0.89 -34 -62 -105 -128
Total Preferred & Common Equity
18 10 -0.53 5.18 44 22 0.89 -34 -62 -105 -128
Preferred Stock
0.56 7.24 7.24 7.22 0.54 0.53 0.53 0.51 0.50 0.50 0.49
Total Common Equity
17 3.05 -7.77 -2.04 43 22 0.37 -34 -62 -105 -128
Common Stock
158 167 173 194 260 262 271 275 292 296 304
Retained Earnings
-140 -164 -181 -196 -216 -240 -271 -310 -354 -402 -433

Quarterly Balance Sheets for Galectin Therapeutics

This table presents Galectin Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
22 26 28 29 9.53 16 13 16 15 13
Total Current Assets
22 25 27 29 9.29 15 13 16 15 13
Cash & Equivalents
20 24 26 27 7.43 14 12 14 13 12
Prepaid Expenses
1.25 1.91 1.69 1.61 1.85 1.66 1.20 1.58 1.39 1.20
Plant, Property, & Equipment, net
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets
0.55 0.43 0.37 0.31 0.24 0.18 0.14 0.07 0.17 0.10
Other Noncurrent Operating Assets
0.55 0.43 0.37 0.31 0.24 0.18 0.14 0.07 0.17 0.10
Total Liabilities & Shareholders' Equity
22 26 28 29 9.53 16 13 16 15 13
Total Liabilities
73 97 110 121 122 133 136 146 152 46
Total Current Liabilities
11 13 15 25 111 11 136 7.31 152 46
Short-Term Debt
- - - 11 21 0.00 90 - 33 33
Accounts Payable
2.68 3.80 3.70 2.80 6.53 5.87 5.39 3.12 3.73 3.50
Accrued Expenses
7.84 8.84 11 12 6.90 4.85 5.04 4.19 3.99 4.16
Dividends Payable
0.00 0.00 0.06 0.00 0.00 0.06 0.00 0.00 0.06 0.00
Other Current Liabilities
- - - 0.36 76 0.00 36 - 111 5.54
Total Noncurrent Liabilities
63 84 95 96 11 122 0.00 139 0.06 0.04
Long-Term Debt
30 51 62 73 11 120 - 136 0.00 0.00
Other Noncurrent Operating Liabilities
32 33 33 23 0.14 1.54 0.00 2.98 0.06 0.04
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest
1.72 1.72 1.72 1.72 1.72 1.72 1.72 1.72 1.72 1.72
Total Equity & Noncontrolling Interests
-53 -73 -84 -94 -114 -119 -125 -132 -139 -35
Total Preferred & Common Equity
-53 -73 -84 -94 -114 -119 -125 -132 -139 -35
Preferred Stock
0.51 0.50 0.50 0.50 0.50 0.49 0.49 0.48 0.48 0.48
Total Common Equity
-53 -73 -84 -95 -114 -119 -126 -132 -139 -36
Common Stock
291 293 294 295 297 299 301 305 308 415
Retained Earnings
-344 -366 -378 -390 -411 -419 -427 -438 -447 -450

Annual Metrics And Ratios for Galectin Therapeutics

This table displays calculated financial ratios and metrics derived from Galectin Therapeutics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
23,929,244.00 29,396,619.00 35,638,698.00 41,136,738.00 56,886,059.00 57,077,055.00 59,341,305.00 59,426,005.00 61,848,657.00 62,761,825.00 63,180,491.00
DEI Adjusted Shares Outstanding
23,929,244.00 29,396,619.00 35,638,698.00 41,136,738.00 56,886,059.00 57,077,055.00 59,341,305.00 59,426,005.00 61,848,657.00 62,761,825.00 63,180,491.00
DEI Earnings Per Adjusted Shares Outstanding
-0.88 -0.76 -0.49 -0.37 -0.35 -0.41 -0.52 -0.65 -0.72 -0.75 -0.49
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth
-30.17% -6.98% 24.35% 16.27% 1.46% -74.65% -28.16% -25.88% -1.87% -8.67% 43.60%
EBIT Growth
-30.13% -6.98% 24.37% 16.28% 1.21% -74.46% -28.14% -25.81% -1.88% -8.68% 43.52%
NOPAT Growth
-30.13% -6.98% 24.37% 16.28% 1.21% -74.46% -28.73% -27.08% 0.73% -11.45% 52.67%
Net Income Growth
-26.85% -7.04% 24.26% 14.38% 4.36% -76.51% -30.10% -27.02% -5.91% -14.56% 34.46%
EPS Growth
-12.82% 13.64% 35.53% 22.45% -2.63% -5.13% -26.83% -25.00% -13.85% -2.70% 36.84%
Operating Cash Flow Growth
-36.67% 3.38% 3.15% 35.95% -6.57% -89.91% -17.99% -27.76% -6.15% -26.70% 42.84%
Free Cash Flow Firm Growth
-21.05% 13.33% -2.97% 20.24% 15.73% -77.54% -4.81% 137.84% -977.67% 40.28% 50.33%
Invested Capital Growth
32.69% -348.56% 45.35% 41.07% -72.25% -58.55% -174.83% -415.49% 65.50% 15.58% 14.99%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
-4.97% 0.39% 12.04% -4.71% -19.30% -12.73% 1.79% -9.93% 2.86% -2.71% 22.31%
EBIT Q/Q Growth
-4.96% 0.39% 12.05% -4.71% -19.61% -12.71% 1.78% -9.91% 2.86% -2.71% 22.19%
NOPAT Q/Q Growth
-4.96% 0.39% 12.05% -4.71% -19.61% -12.71% 1.33% -9.13% 2.74% -7.25% 31.09%
Net Income Q/Q Growth
-4.92% 0.37% 11.98% -5.05% -18.62% -13.08% 2.03% -9.65% 1.53% -4.37% 17.34%
EPS Q/Q Growth
-2.33% 3.80% 15.52% -265.22% 60.61% -17.14% 3.70% -10.17% 2.63% -4.11% 18.64%
Operating Cash Flow Q/Q Growth
-9.60% -1.64% 5.70% 15.71% -19.26% -8.74% -6.75% -0.94% 7.15% -24.02% 22.04%
Free Cash Flow Firm Q/Q Growth
-9.75% 0.86% -1.47% 16.03% -5.73% -6.56% -11.91% 125.13% -1,183.79% 1.47% -42.30%
Invested Capital Q/Q Growth
52.32% 18.66% 58.21% 9.43% -112.75% -184.42% 1.56% -384.56% 65.42% 67.02% 77.69%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent
99.74% 99.79% 99.93% 102.19% 98.93% 100.09% 101.62% 102.60% 106.65% 112.43% 130.48%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-75.54% -115.67% -245.84% -343.59% -50.65% -67.25% -227.74% 262.19% 88.85% 57.62% 26.90%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
-54.30% -64.09% 87.78% 416.72% -39.84% -62.90% -189.51% 301.93% 93.14% 59.19% 27.42%
Return on Equity Simple (ROE_SIMPLE)
-111.01% -208.28% 3,063.21% -268.60% -30.30% -104.43% -3,418.48% 114.33% 66.27% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-14 -15 -11 -9.52 -9.41 -16 -21 -27 -27 -30 -14
NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
-21.78% -31.16% -53.20% -80.05% -14.04% -18.94% -49.98% -124.23% 76.92% 25.26% 16.19%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - - -272.58% -2,072.79% -241.70%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-20 -21 -16 -14 -13 -23 -30 -38 -39 -42 -24
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-20 -21 -16 -14 -13 -23 -30 -38 -38 -42 -24
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
2.24 9.43 0.00 0.00 3.75 5.83 335.62 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)
2.25 9.44 0.00 0.00 3.75 5.83 335.62 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 9.97 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 11.10 -0.31 -1.19 -1.03 -1.06
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 11.10 -0.31 -1.19 -0.83 -1.06
Financial Leverage
-1.03 -1.11 -1.38 -1.35 -1.05 -1.07 -1.40 0.65 -0.41 -0.84 -0.90
Leverage Ratio
1.06 1.14 1.51 1.63 1.09 1.12 2.66 -2.13 -0.54 -0.28 -0.16
Compound Leverage Factor
1.06 1.14 1.51 1.66 1.08 1.12 2.71 -2.19 -0.57 -0.31 -0.21
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 91.74% -44.17% 623.83% 3,365.84% 1,773.67%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 669.11% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 91.74% -44.17% 623.83% 2,696.74% 1,773.67%
Preferred Equity to Total Capital
2.22% 60.25% 606.79% 104.65% 1.18% 2.18% 1.66% -2.28% 4.35% 15.84% 6.50%
Noncontrolling Interests to Total Capital
27.98% 14.34% 144.43% 24.98% 3.78% 7.12% 5.44% -7.72% 14.98% 54.59% 22.85%
Common Equity to Total Capital
69.80% 25.41% -651.22% -29.63% 95.04% 90.70% 1.16% 154.17% -543.17% -3,336.28% -1,703.02%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 -0.97 -0.26 -1.86 -2.54 -5.67
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.35 0.23 -1.20 -2.18 -4.92
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 -0.97 -0.26 -1.86 -2.04 -5.67
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 -1.38 -0.37 -2.69 -3.58 -9.51
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.50 0.33 -1.73 -3.07 -8.25
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 -1.38 -0.37 -2.69 -2.87 -9.51
Altman Z-Score
8.52 -13.51 -49.53 5.57 27.95 1.20 -8.61 -25.04 -20.89 -40.87 0.00
Noncontrolling Interest Sharing Ratio
28.12% 44.59% 135.71% 221.28% 21.34% 6.46% 16.79% -15.16% -4.82% -2.72% -1.93%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
19.41 4.18 1.29 4.19 17.10 5.46 4.63 1.58 1.77 0.49 2.42
Quick Ratio
19.00 4.06 1.03 3.92 16.84 5.03 4.39 1.43 1.64 0.43 2.21
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-14 -12 -13 -10 -8.64 -15 -16 6.09 -53 -32 -16
Operating Cash Flow to CapEx
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 -1,071.66 -30.53 -99.35 -176.39 -32.89 5.89 -19.13 -5.76 -2.16
Operating Cash Flow to Interest Expense
0.00 0.00 -1,324.33 -30.29 -124.69 -236.79 -49.71 -30.06 -11.81 -7.54 -3.26
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 -1,324.33 -30.29 -124.69 -236.79 -49.71 -30.06 -11.81 -7.54 -3.26
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-0.73 -3.28 -1.79 -1.06 -1.82 -2.88 -7.93 -41 -14 -12 -10
Invested Capital Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
0.36 -2.55 1.49 0.74 -0.76 -1.07 -5.04 -33 27 2.20 1.78
Enterprise Value (EV)
21 22 125 142 117 103 114 61 151 174 0.00
Market Capitalization
39 29 119 141 163 128 123 67 103 81 0.00
Book Value per Share
$0.73 $0.10 ($0.22) ($0.05) $0.76 $0.38 $0.01 ($0.58) ($1.01) ($1.68) ($2.01)
Tangible Book Value per Share
$0.73 $0.10 ($0.22) ($0.05) $0.76 $0.38 $0.01 ($0.58) ($1.01) ($1.68) ($2.01)
Total Capital
25 12 1.19 6.90 46 24 32 -22 12 3.16 7.54
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00 29 9.86 72 106 134
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 29 9.86 72 85 134
Net Debt
-26 -15 -3.05 -8.25 -47 -27 -11 -8.73 46 91 116
Capital Expenditures (CapEx)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-0.81 -3.35 -2.20 -1.53 -2.09 -3.08 -6.86 -11 -14 -12 -6.31
Debt-free Net Working Capital (DFNWC)
25 12 0.85 6.72 45 24 33 7.54 12 2.96 11
Net Working Capital (NWC)
25 12 0.85 6.72 45 24 33 7.54 12 -18 11
Net Nonoperating Expense (NNE)
5.97 6.40 4.86 4.38 3.89 7.05 9.40 12 14 17 17
Net Nonoperating Obligations (NNO)
-26 -15 -2.99 -7.95 -47 -27 -11 -8.66 46 91 116
Total Depreciation and Amortization (D&A)
0.01 0.01 0.00 0.00 0.04 0.04 0.04 0.03 0.03 0.04 0.05
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.88) ($0.76) ($0.49) ($0.38) ($0.39) ($0.41) ($0.52) ($0.65) ($0.74) ($0.76) ($0.48)
Adjusted Weighted Average Basic Shares Outstanding
28.83M 34.06M 37.57M 45.55M 57.03M 57.16M 58.53M 59.39M 60.16M 62.31M 63.90M
Adjusted Diluted Earnings per Share
($0.88) ($0.76) ($0.49) ($0.38) ($0.39) ($0.41) ($0.52) ($0.65) ($0.74) ($0.76) ($0.48)
Adjusted Weighted Average Diluted Shares Outstanding
28.83M 34.06M 37.57M 45.55M 57.03M 57.16M 58.53M 59.39M 60.16M 62.31M 63.90M
Adjusted Basic & Diluted Earnings per Share
($0.88) ($0.76) ($0.49) ($0.38) ($0.39) ($0.41) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
24.12M 29.22M 35.52M 39.41M 52.24M 57.03M 59.36M 59.44M 61.90M 63.18M 0.00
Normalized Net Operating Profit after Tax (NOPAT)
-14 -15 -11 -9.52 -9.41 -16 -21 -27 -27 -30 -14
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 -1,353.92 -40.48 -154.46 -269.47 -61.43 -36.59 -13.79 -7.55 -3.22
NOPAT to Interest Expense
0.00 0.00 -947.74 -28.34 -108.12 -188.63 -43.20 -25.99 -9.55 -5.36 -1.92
EBIT Less CapEx to Interest Expense
0.00 0.00 -1,353.92 -40.48 -154.46 -269.47 -61.43 -36.59 -13.79 -7.55 -3.22
NOPAT Less CapEx to Interest Expense
0.00 0.00 -947.74 -28.34 -108.12 -188.63 -43.20 -25.99 -9.55 -5.36 -1.92
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% -2.96% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% -2.96% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Galectin Therapeutics

This table displays calculated financial ratios and metrics derived from Galectin Therapeutics' official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
61,903,672.00 62,148,134.00 62,278,125.00 62,761,825.00 63,180,491.00 63,180,491.00 63,180,491.00 63,180,491.00 63,180,491.00 65,856,898.00 100,849,644.00
DEI Adjusted Shares Outstanding
61,903,672.00 62,148,134.00 62,278,125.00 62,761,825.00 63,180,491.00 63,180,491.00 63,180,491.00 63,180,491.00 63,180,491.00 65,856,898.00 100,849,644.00
DEI Earnings Per Adjusted Shares Outstanding
-0.19 -0.20 -0.18 -0.19 -0.15 -0.12 -0.13 -0.09 -0.08 -0.14 -0.04
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth
5.07% -31.09% -1.69% -11.96% 24.77% 48.86% 34.73% 65.63% 61.05% -24.72% 57.16%
EBIT Growth
5.35% -31.34% -1.70% -11.96% 24.67% 48.84% 34.79% 65.27% 60.94% -24.75% 56.69%
NOPAT Growth
6.71% -25.41% 1.09% -29.99% 18.15% 59.04% 53.70% 72.92% 48.37% 13.90% 19.80%
Net Income Growth
0.33% -35.74% -7.59% -19.71% 16.17% 39.20% 27.06% 54.04% 47.61% -21.17% 56.85%
EPS Growth
0.00% -33.33% 25.00% -18.75% 21.05% 40.00% 27.78% 57.89% 46.67% -16.67% 69.23%
Operating Cash Flow Growth
-12.16% 15.25% -11.80% -172.03% 36.48% 20.77% 58.51% 52.76% 49.72% 63.06% 36.05%
Free Cash Flow Firm Growth
-153.45% -105.97% -142.55% 67.43% 262.28% -2,705.61% 157.42% 62.01% -311.11% 369.95% -664.99%
Invested Capital Growth
28.34% -16.71% 11.48% 15.58% -102.23% 77.17% -25.69% 14.99% 90.14% -1,023.32% 73.68%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
-14.13% -6.32% 12.27% -5.17% 23.31% 27.72% -11.96% 44.62% 13.09% -131.44% 61.54%
EBIT Q/Q Growth
-14.02% -6.32% 12.19% -5.17% 23.29% 27.78% -11.92% 43.98% 13.74% -130.67% 61.15%
NOPAT Q/Q Growth
-0.91% -17.03% 19.71% -37.08% 36.46% 41.43% 9.23% 19.84% -21.16% 2.33% 15.44%
Net Income Q/Q Growth
-14.92% -7.68% 9.30% -6.66% 19.52% 21.91% -8.82% 32.80% 8.25% -80.60% 61.25%
EPS Q/Q Growth
-18.75% -5.26% 10.00% -5.56% 21.05% 20.00% -8.33% 38.46% 0.00% -75.00% 71.43%
Operating Cash Flow Q/Q Growth
-157.44% 31.16% -2.46% -49.81% 39.89% 14.14% 46.35% -70.58% 36.01% 36.91% 7.13%
Free Cash Flow Firm Q/Q Growth
28.61% 94.26% -704.42% 1.18% 455.70% -199.23% 116.46% -165.38% -1,876.49% 226.88% -134.46%
Invested Capital Q/Q Growth
-207.28% -5.35% 20.94% 67.02% -636.08% 88.11% -335.36% 77.69% 14.62% -1,254.67% 89.80%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent
109.24% 110.63% 114.27% 115.88% 121.57% 131.46% 127.82% 153.33% 163.09% 127.69% 127.34%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
72.15% 66.46% 62.89% 57.62% 49.29% 40.48% 34.53% 26.90% 21.65% 21.92% 29.54%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
74.98% 68.68% 64.84% 59.19% 50.49% 41.38% 35.24% 27.42% 22.05% 22.30% 30.37%
Return on Equity Simple (ROE_SIMPLE)
56.35% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-6.75 -7.90 -6.35 -8.70 -5.53 -3.24 -2.94 -2.36 -2.85 -2.79 -2.36
NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
94.99% 18.41% 14.66% 4.76% 15.65% 5.98% 7.79% 3.03% 3.00% 9.99% 2.35%
Return On Investment Capital (ROIC_SIMPLE)
31.43% 36.22% 59.07% -607.09% 6.75% -206.47% 8.27% -40.49% -76.10% 2.64% 120.68%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-11 -11 -9.82 -10 -7.92 -5.72 -6.40 -3.59 -3.09 -7.14 -2.77
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-11 -11 -9.81 -10 -7.91 -5.72 -6.40 -3.55 -3.08 -7.13 -2.74
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 6.58 0.00 0.00 0.00 0.00 3.42 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
-0.72 -0.76 -0.90 -1.03 -0.29 -1.03 -0.73 -1.06 -1.04 -0.24 -0.99
Long-Term Debt to Equity
-0.72 -0.76 -0.79 -0.83 -0.10 -1.03 0.00 -1.06 -1.04 0.00 0.00
Financial Leverage
-0.09 -0.36 -0.46 -0.84 -0.29 -0.72 -0.62 -0.90 -0.60 -0.50 -0.64
Leverage Ratio
-0.41 -0.36 -0.36 -0.28 -0.19 -0.22 -0.19 -0.16 -0.10 -0.12 -0.16
Compound Leverage Factor
-0.44 -0.40 -0.41 -0.32 -0.23 -0.29 -0.25 -0.25 -0.17 -0.15 -0.21
Debt to Total Capital
-259.71% -308.67% -925.17% 3,365.84% -40.03% 3,660.22% -265.34% 1,773.67% 2,479.63% -31.83% -14,438.70%
Short-Term Debt to Total Capital
0.00% 0.00% -116.59% 669.11% -26.54% 0.00% -265.34% 0.00% 0.00% -31.83% -14,438.70%
Long-Term Debt to Total Capital
-259.71% -308.67% -808.58% 2,696.74% -13.49% 3,660.22% 0.00% 1,773.67% 2,479.63% 0.00% 0.00%
Preferred Equity to Total Capital
-2.53% -2.49% -5.54% 15.84% -0.62% 14.89% -1.45% 6.50% 8.77% -0.46% -208.70%
Noncontrolling Interests to Total Capital
-8.72% -8.57% -19.10% 54.59% -2.15% 52.35% -5.09% 22.85% 31.48% -1.66% -749.13%
Common Equity to Total Capital
370.96% 419.73% 1,049.82% -3,336.28% 142.80% -3,627.47% 371.88% -1,703.02% -2,419.88% 133.95% 15,496.52%
Debt to EBITDA
-1.35 -1.53 -2.05 -2.54 -0.82 -3.57 -2.96 -5.67 -7.24 -1.64 -2.01
Net Debt to EBITDA
-0.73 -0.90 -1.39 -2.18 -0.63 -3.16 -2.58 -4.92 -6.49 -0.98 -1.30
Long-Term Debt to EBITDA
-1.35 -1.53 -1.79 -2.04 -0.28 -3.57 0.00 -5.67 -7.24 0.00 0.00
Debt to NOPAT
-1.96 -2.23 -3.01 -3.58 -1.13 -5.06 -4.40 -9.51 -11.92 -3.02 -3.21
Net Debt to NOPAT
-1.06 -1.31 -2.04 -3.07 -0.87 -4.48 -3.83 -8.25 -10.68 -1.81 -2.08
Long-Term Debt to NOPAT
-1.96 -2.23 -2.63 -2.87 -0.38 -5.06 0.00 -9.51 -11.92 0.00 0.00
Altman Z-Score
-19.62 -19.17 -18.95 -34.93 -75.57 -37.83 0.00 0.00 0.00 -53.65 -47.21
Noncontrolling Interest Sharing Ratio
-3.92% -3.34% -3.11% -2.72% -2.42% -2.23% -2.05% -1.93% -1.83% -1.74% -2.81%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
2.02 1.87 1.13 0.49 0.08 1.43 0.09 2.42 2.15 0.10 0.28
Quick Ratio
1.86 1.75 1.07 0.43 0.07 1.28 0.08 2.21 1.93 0.09 0.25
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-24 -1.37 -11 -11 39 -38 6.33 -4.14 -82 104 -36
Operating Cash Flow to CapEx
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense
-22.70 -1.08 -7.38 -6.32 22.22 -21.06 3.48 -2.13 -41.16 51.80 -45.51
Operating Cash Flow to Interest Expense
-11.51 -6.57 -5.71 -7.42 -4.41 -3.62 -1.95 -3.12 -1.94 -1.22 -2.88
Operating Cash Flow Less CapEx to Interest Expense
-11.51 -6.57 -5.71 -7.42 -4.41 -3.62 -1.95 -3.12 -1.94 -1.22 -2.88
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-43 -46 -36 -12 -88 -10 -45 -10 -8.64 -117 -12
Invested Capital Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
17 -6.53 4.68 2.20 -44 35 -9.27 1.78 79 -107 33
Enterprise Value (EV)
178 179 230 174 104 242 0.00 0.00 0.00 328 415
Market Capitalization
148 140 171 81 77 133 0.00 0.00 0.00 306 391
Book Value per Share
($1.18) ($1.36) ($1.52) ($1.68) ($1.82) ($1.88) ($1.96) ($2.01) ($2.01) ($2.11) ($0.35)
Tangible Book Value per Share
($1.18) ($1.36) ($1.52) ($1.68) ($1.82) ($1.88) ($1.96) ($2.01) ($2.01) ($2.11) ($0.35)
Total Capital
-20 -20 -9.02 3.16 -80 3.29 -34 7.54 5.47 -104 -0.23
Total Debt
51 62 83 106 32 120 90 134 136 33 33
Total Long-Term Debt
51 62 73 85 11 120 0.00 134 136 0.00 0.00
Net Debt
28 36 56 91 25 107 78 116 122 20 22
Capital Expenditures (CapEx)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-11 -13 -13 -12 -88 -9.12 -45 -6.31 -5.73 -117 -12
Debt-free Net Working Capital (DFNWC)
13 13 14 2.96 -80 4.65 -34 11 8.38 -104 -0.29
Net Working Capital (NWC)
13 13 3.41 -18 -102 4.65 -124 11 8.38 -137 -34
Net Nonoperating Expense (NNE)
4.74 4.47 4.87 3.27 4.10 4.28 5.25 3.14 2.19 6.33 1.17
Net Nonoperating Obligations (NNO)
28 37 56 91 25 107 78 116 122 20 22
Total Depreciation and Amortization (D&A)
0.00 0.00 0.01 0.01 0.01 0.00 0.00 0.04 0.01 0.00 0.03
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.19) ($0.20) ($0.18) ($0.19) ($0.15) ($0.12) ($0.13) ($0.08) ($0.08) ($0.14) ($0.04)
Adjusted Weighted Average Basic Shares Outstanding
61.98M 62.23M 62.28M 62.31M 63.20M 63.45M 64.21M 63.90M 65.78M 65.88M 89.62M
Adjusted Diluted Earnings per Share
($0.19) ($0.20) ($0.18) ($0.19) ($0.15) ($0.12) ($0.13) ($0.08) ($0.08) ($0.14) ($0.04)
Adjusted Weighted Average Diluted Shares Outstanding
61.98M 62.23M 62.28M 62.31M 63.20M 63.45M 64.21M 63.90M 65.78M 65.88M 89.62M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
62.15M 62.28M 62.76M 63.18M 0.00 0.00 0.00 0.00 65.86M 100.85M 100.88M
Normalized Net Operating Profit after Tax (NOPAT)
-6.75 -7.90 -6.35 -8.70 -5.53 -3.24 -2.94 -2.36 -2.85 -2.79 -2.36
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
-10.00 -8.81 -6.57 -5.99 -4.54 -3.13 -3.52 -1.85 -1.56 -3.56 -3.53
NOPAT to Interest Expense
-6.42 -6.23 -4.25 -5.04 -3.17 -1.77 -1.61 -1.21 -1.44 -1.39 -3.00
EBIT Less CapEx to Interest Expense
-10.00 -8.81 -6.57 -5.99 -4.54 -3.13 -3.52 -1.85 -1.56 -3.56 -3.53
NOPAT Less CapEx to Interest Expense
-6.42 -6.23 -4.25 -5.04 -3.17 -1.77 -1.61 -1.21 -1.44 -1.39 -3.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Galectin Therapeutics remains a development-stage biotechnology company with no reported revenue. Its financial statements show continued operating losses and cash consumption, although quarterly operating expenses and cash burn have generally improved from the elevated levels seen in early 2024.

  • Operating expenses have declined. Total operating expenses were $4.0 million in Q2 2026, down from $4.6 million in Q2 2025 and $9.6 million in Q1 2024. Research and development spending also fell to $2.1 million from $3.3 million a year earlier.
  • Operating cash burn has improved from 2024 levels. Net cash used in operating activities was $2.4 million in Q2 2026, compared with $7.7 million in Q1 2024 and $8.3 million in Q2 2024.
  • The company still held $13.3 million in cash and equivalents at June 30, 2026. This provides some funding for research and corporate activities, although the balance declined from $14.1 million at the end of Q1 2026.
  • Financing activity has continued to provide liquidity. Galectin generated $1.6 million from financing activities in Q2 2026, following $12.2 million in Q4 2025 and $12.9 million in Q2 2025.
  • Quarterly losses have been volatile. The Q2 2026 net loss was $9.1 million, compared with $5.0 million in Q1 2026 and $5.5 million in Q4 2025. The latest loss was amplified by $3.2 million of other expense and $2.0 million of interest expense.
  • Interest expense remains a significant burden. Quarterly interest expense increased from $1.1 million in Q1 2024 to $2.0 million in Q2 2026, absorbing a substantial portion of the company’s available cash resources.
  • Galectin has not generated operating revenue. Reported revenue was $0 in the periods provided, leaving the company dependent on financing, potential strategic transactions or future product development success.
  • The balance sheet shows severely negative equity. Total equity and noncontrolling interests were negative $138.6 million at June 30, 2026, compared with negative $114.0 million at March 31, 2024. Retained earnings were negative $446.8 million.
  • Liabilities substantially exceed assets. Total liabilities were $151.7 million against just $14.8 million of assets in Q2 2026. Total current liabilities of $151.6 million also greatly exceeded current assets of $14.7 million, indicating significant balance-sheet and liquidity pressure.
  • Ongoing cash burn creates refinancing risk. At the Q2 2026 operating cash-burn rate, the cash balance equates to roughly five quarters of operating funding before considering debt obligations, interest payments and changes in spending. Additional capital could be required sooner if clinical development costs rise or financing becomes less available.

Overall, the statements show some improvement in research spending and operating cash burn, but Galectin continues to lack revenue, post substantial net losses and carry liabilities far above its asset base. For investors, the company’s ability to secure additional financing and advance its pipeline remains more important than traditional earnings or revenue growth metrics.

11/17/26 02:00 AM ETAI Generated. May Contain Errors.

Galectin Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Galectin Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Galectin Therapeutics' net income appears to be on a downward trend, with a most recent value of -$30.84 million in 2025, falling from -$20.03 million in 2015. The previous period was -$47.05 million in 2024. Check out Galectin Therapeutics' forecast to explore projected trends and price targets.

Galectin Therapeutics' total operating income in 2025 was -$20.09 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $20.09 million

Over the last 10 years, Galectin Therapeutics' total revenue changed from $0.00 in 2015 to $0.00 in 2025, a change of 0.0%.

In the past 12 quarters, Galectin Therapeutics' cash and equivalents has ranged from $7.43 million in Q1 2025 to $27.06 million in Q3 2024, and is currently $11.71 million as of their latest financial filing in Q3 2026.

Galectin Therapeutics had total debt of $133.74 million at the end of 2025, a 25.9% increase from 2024, and none in 2015.

Over the last 10 years, Galectin Therapeutics' book value per share changed from 0.73 in 2015 to -2.01 in 2025.



Financial statements for NASDAQ:GALT last updated on 11/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners